{
    "clinical_study": {
        "@rank": "124611", 
        "arm_group": [
            {
                "arm_group_label": "1", 
                "arm_group_type": "Experimental", 
                "description": "Participants will receive cyclophosphamide IV over 60 minutes on Days -5 to -2 with antithymocyte globulin IV over 4 hours; then, after the last does cycophosphamide, participants will receive a bone marrow transplant over 60 to 120 minutes on Day 0."
            }, 
            {
                "arm_group_label": "2", 
                "arm_group_type": "Experimental", 
                "description": "Participants will receive cyclophosphamide IV over 60 minutes on Days -5 to -2; then, after the last does cycophosphamide, participants will receive a bone marrow transplant over 60 to 120 minutes on Day 0."
            }
        ], 
        "brief_summary": {
            "textblock": "OBJECTIVES:\n\n      I.  Compare outcome, including graft failure, graft versus host disease, and survival of\n      HLA-identical sibling bone marrow transplants for aplastic anemia using cyclophosphamide\n      with or without antithymocyte globulin as a conditioning regimen."
        }, 
        "brief_title": "Phase III Randomized Study of Cyclophosphamide With or Without Antithymocyte Globulin Before Bone Marrow Transplantation in Patients With Aplastic Anemia", 
        "completion_date": {
            "#text": "August 2007", 
            "@type": "Actual"
        }, 
        "condition": "Aplastic Anemia", 
        "condition_browse": {
            "mesh_term": [
                "Anemia", 
                "Anemia, Aplastic"
            ]
        }, 
        "detailed_description": {
            "textblock": "PROTOCOL OUTLINE: This is a randomized, multicenter study. Patients are randomized to\n      receive cyclophosphamide IV over 60 minutes on days -5 to -2 with or without antithymocyte\n      globulin IV over 4 hours.\n\n      All patients then receive bone marrow over 60-120 minutes on day 0, 36 hours after the last\n      dose of cyclophosphamide.\n\n      Patients are followed at day 100, at 6 months, and at 1 year posttransplant."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "PROTOCOL ENTRY CRITERIA:\n\n        --Disease Characteristics--\n\n        Severe aplastic anemia with the following criteria:\n\n        Hypocellular bone marrow with cellularity less than 20%\n\n        At least 2 of the following hematologic abnormalities:\n\n          -  Neutrophil count no greater than 500/mm3\n\n          -  Platelet count no greater than 20,000/mm3\n\n          -  Reticulocyte count no greater than 50,000/mm3\n\n        HLA-identical sibling donor available\n\n        No clonal cytogenetic abnormalities, paroxysmal nocturnal hemoglobinuria, or\n        myelodysplastic syndrome within 3 months of diagnosis of aplastic anemia\n\n        No congenital or constitutional aplastic anemia or Fanconi anemia\n\n        --Patient Characteristics--\n\n        Hepatic: Bilirubin less than 3 times upper limit of normal (ULN)\n\n        Renal: Creatinine less than 2 times ULN\n\n        Cardiovascular: Normal cardiac function\n\n        Other:\n\n          -  No uncontrolled infection\n\n          -  No severe concurrent disease\n\n          -  HIV negative\n\n          -  Fertile patients must use effective contraception"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "59 Years", 
            "minimum_age": "N/A"
        }, 
        "enrollment": "224", 
        "firstreceived_date": "October 18, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00004474", 
            "org_study_id": "199/14004", 
            "secondary_id": [
                "RPCI-RP-9804", 
                "NCI-G98-1491", 
                "IBMTR-1"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "1", 
                "description": "Given via IV over 4 hours", 
                "intervention_name": "Anti-thymocyte globulin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "1", 
                    "2"
                ], 
                "description": "Given via IV over 60 minutes on Days -5 to -2", 
                "intervention_name": "Cyclophosphamide", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "1", 
                    "2"
                ], 
                "description": "Given on Day 0", 
                "intervention_name": "Bone marrow transplantation", 
                "intervention_type": "Procedure"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Antilymphocyte Serum", 
                "Cyclophosphamide"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Hematologic Disorders", 
            "Rare Disease"
        ], 
        "lastchanged_date": "October 1, 2008", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Buffalo", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "14263-0001"
                    }, 
                    "name": "Roswell Park Cancer Institute"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77030-4009"
                    }, 
                    "name": "University of Texas - MD Anderson Cancer Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Milwaukee", 
                        "country": "United States", 
                        "state": "Wisconsin", 
                        "zip": "53226"
                    }, 
                    "name": "Medical College of Wisconsin"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Milwaukee", 
                        "country": "United States", 
                        "state": "Wisconsin", 
                        "zip": "53226"
                    }, 
                    "name": "Midwest Children's Cancer Center"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase III Randomized Study of Cyclophosphamide With or Without Antithymocyte Globulin Before Bone Marrow Transplantation in Patients With Aplastic Anemia", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "August 2007", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Graft failure, graft versus host disease, and survival", 
            "safety_issue": "Yes", 
            "time_frame": "Measured at Day 100, Month 6, and Year 1 post-transplant"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00004474"
        }, 
        "responsible_party": {
            "name_title": "Richard Champlin", 
            "organization": "University of Texas - MD Anderson Cancer Center"
        }, 
        "source": "Office of Rare Diseases (ORD)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Roswell Park Cancer Institute", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 1998", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2008"
    }, 
    "geocoordinates": {
        "Medical College of Wisconsin": "43.039 -87.906", 
        "Midwest Children's Cancer Center": "43.039 -87.906", 
        "Roswell Park Cancer Institute": "42.886 -78.878", 
        "University of Texas - MD Anderson Cancer Center": "29.76 -95.369"
    }
}